Ganapathi S K, Beggs A D, Hodgson S V, Kumar D
Department of Colorectal Surgery, St. George's Hospital, London, UK.
Department of Cancer Genetics, St. George's University of London, London, UK.
Br J Cancer. 2014 Oct 14;111(8):1581-9. doi: 10.1038/bjc.2014.477. Epub 2014 Sep 16.
Colorectal cancer (CRC) progression is associated with suppression of host cell-mediated immunity and local immune escape mechanisms. Our aim was to assess the immune function in terms of expression of TNF, IFNG and FOXP3 in CRC.
Sixty patients with CRC and 15 matched controls were recruited. TaqMan quantitative PCR and methylation-specific PCR was performed for expression and DNA methylation analysis of TNF, IFNG and FOXP3. Survival analysis was performed over a median follow-up of 48 months.
TNF was suppressed in tumour and IFNG was suppressed in peripheral blood mononuclear cells (PBMCs) of patients with CRC. Tumours showed enhanced expression of FOXP3 and was significantly higher when tumour size was >38 mm (median tumour size; P=0.006, Mann-Whitney U-test). Peripheral blood mononuclear cell IFNG was suppressed in recurrent CRC (P=0.01). Methylated TNFpromoter (P=0.003) and TNFexon1 (P=0.001) were associated with significant suppression of TNF in tumours. Methylated FOXP3cpg was associated with significant suppression of FOXP3 in both PBMC (P=0.018) and tumours (P=0.010). Reduced PBMC FOXP3 expression was associated with significantly worse overall survival (HR=8.319, P=0.019).
We have detected changes in the expression of immunomodulatory genes that could act as biomarkers for prognosis and future immunotherapeutic strategies.
结直肠癌(CRC)的进展与宿主细胞介导的免疫抑制和局部免疫逃逸机制有关。我们的目的是根据CRC中TNF、IFNG和FOXP3的表达来评估免疫功能。
招募了60例CRC患者和15例匹配的对照。采用TaqMan定量PCR和甲基化特异性PCR对TNF、IFNG和FOXP3进行表达和DNA甲基化分析。在中位随访48个月期间进行生存分析。
CRC患者肿瘤中的TNF受到抑制,外周血单个核细胞(PBMC)中的IFNG受到抑制。肿瘤显示FOXP3表达增强,当肿瘤大小>38mm(中位肿瘤大小)时显著更高(P=0.006,Mann-Whitney U检验)。复发性CRC外周血单个核细胞中的IFNG受到抑制(P=0.01)。甲基化的TNF启动子(P=0.003)和TNF外显子1(P=0.001)与肿瘤中TNF的显著抑制相关。甲基化的FOXP3 CpG与PBMC(P=0.018)和肿瘤(P=0.010)中FOXP3的显著抑制相关。PBMC中FOXP3表达降低与总体生存率显著更差相关(HR=8.319,P=0.019)。
我们检测到免疫调节基因表达的变化,这些变化可能作为预后和未来免疫治疗策略的生物标志物。